Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Molecular Mechanisms Involved in the Medical Treatment of Pulmonary Arterial Hypertension

  • Martín de Miguel, Irene
  • Cruz Utrilla, Alejandro
  • Oliver, Eduardo
  • Escribano-Subias, Pilar
Pulmonary arterial hypertension (PAH) is a severe condition with a high mortality rate despite advances in diagnostic and therapeutic strategies. In recent years, significant scientific progress has been made in the understanding of the underlying pathobiological mechanisms. Since current available treatments mainly target pulmonary vasodilation, but lack an effect on the pathological changes that develop in the pulmonary vasculature, there is need to develop novel therapeutic compounds aimed at antagonizing the pulmonary vascular remodeling. This review presents the main molecular mechanisms involved in the pathobiology of PAH, discusses the new molecular compounds currently being developed for the medical treatment of PAH and assesses their potential future role in the therapeutic algorithms of PAH., Eduardo Oliver is a recipient of funds from Proyectos de Generación de Conocimiento (PID2021-123167OB-I00) and from a Ramón y Cajal grant (RYC2020-028884-I) funded by MCIN/AEI/ 10.13039/501100011033 and by “ESF Investing in your future”. P.E-S. has received research grants from Janssen., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of UCP2 in the energy metabolism of the cancer cell line A549

  • Segalés, Jessica
  • Sánchez-Martín, Carlos
  • Pujol, Aleida
  • Martín-Ruiz, Marta
  • De los Santos, Patricia
  • Lobato-Alonso, Daniel
  • Oliver, Eduardo
  • Rial, Eduardo
12 p.-5 fig., The uncoupling protein UCP2 is a mitochondrial carrier for which transport activity remains controversial. The physiological contexts in which UCP2 is expressed have led to the assumption that, like UCP1, it uncouples oxidative phosphorylation and thereby reduces the generation of reactive oxygen species. Other reports have involved UCP2 in the Warburg effect, and results showing that UCP2 catalyzes the export of matrix C4 metabolites to facilitate glutamine utilization suggest that the carrier could be involved in the metabolic adaptations required for cell proliferation. We have examined the role of UCP2 in the energy metabolism of the lung adenocarcinoma cell line A549 and show that UCP2 silencing decreased the basal rate of respiration, although this inhibition was not compensated by an increase in glycolysis. Silencing did not lead to either changes in proton leakage, as determined by the rate of respiration in the absence of ATP synthesis, or changes in the rate of formation of reactive oxygen species. The decrease in energy metabolism did not alter the cellular energy charge. The decreased cell proliferation observed in UCP2-silenced cells would explain the reduced cellular ATP demand. We conclude that UCP2 does not operate as an uncoupling protein, whereas our results are consistent with its activity as a C4-metabolite carrier involved in the metabolic adaptations of proliferating cells., This research was funded by grants (SAF2010-20256, PID2019-108166GB-I00, and Redox Biology and Medicine Network RED2018-102576-T to E.R. and PID2021-123167OB-I00 and a Ramón y Cajal RYC2020-028884-I to E.O.) from the Spanish Ministry of Science and Innovation (MCIN/AEI/10.13039/501100011033). P.d.l.S. was supported by a Garantía Juvenil contract of the Comunidad de Madrid (PEJ-2020-TL/BMD-18670). D.L.-A. was funded by the Programa Investigo from the Comunidad de Madrid and European Union-Next Generation EU (09-PIN1-00004.3/2022)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

β3-Adrenergic receptor overexpression in cardiomyocytes preconditions mitochondria to withstand ischemia-reperfusion injury

  • Fernández-Tocino, Miguel
  • Pun-García, Andrés
  • Gómez, Mónica
  • Clemente-Moragón, Agustín
  • Oliver, Eduardo
  • Villena-Gutiérrez, Rocío
  • Trigo-Anca, Sofía
  • Díaz-Guerra, Anabel
  • Sanz-Rosa, David
  • Prados, Belén
  • Del Campo, Lara
  • Andrés, Vicente
  • Fuster, Valentín
  • de la Pompa, José Luis
  • Cádiz, Laura
  • Ibáñez, Borja
22 p.-7 fig., β3-Adrenergic receptor (β3AR) agonists have been shown to protect against ischemia-reperfusion injury (IRI). Since β3ARs are present both in cardiomyocytes and in endothelial cells, the cellular compartment responsible for this protection has remained unknown. Using transgenic mice constitutively expressing the human β3AR (hβ3AR) in cardiomyocytes or in the endothelium on a genetic background of null endogenous β3AR expression, we show that only cardiomyocyte expression protects against IRI (45 min ischemia followed by reperfusion over 24 h). Infarct size was also limited after ischemia-reperfusion in mice with cardiomyocyte hβ3AR overexpression on top of endogenous β3AR expression. hβ3AR overexpression in these mice reduced IRI-induced cardiac fibrosis and improved long-term left ventricular systolic function. Cardiomyocyte-specific β3AR overexpression resulted in a baseline remodeling of the mitochondrial network, characterized by upregulated mitochondrial biogenesis and a downregulation of mitochondrial quality control (mitophagy), resulting in elevated numbers of small mitochondria with a depressed capacity for the generation of reactive oxygen species but improved capacity for ATP generation. These processes precondition cardiomyocyte mitochondria to be more resistant to IRI. Upon reperfusion, hearts with hβ3AR overexpression display a restoration in the mitochondrial quality control and a rapid activation of antioxidant responses. Strong protection against IRI was also observed in mice infected with an adeno-associated virus (AAV) encoding hβ3AR under a cardiomyocyte-specific promoter. These results confirm the translational potential of increased cardiomyocyte β3AR expression, achieved either naturally through exercise or artificially through gene therapy approaches, to precondition the cardiomyocyte mitochondrial network to withstand future insults., This study received funding from the Spanish Ministry of Science, Innovation and Universities (PID2022-140176OB-I00 to B.I, and PID2022-104776RB-100 to J.L.d.l.P), the European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Programme (ERC-Consolidator Grant agreement No. 819775 to B.I), the Comunidad de Madrid through the Red Madrileña de Nanomedicina en Imagen Molecular (P2022/BMD-7403 RENIM-CM), and the CIBERCV (CB16/11/00358 to B.I, and CB16/11/00399 to J.L.d.l.P). Miguel Fernández-Tocino holds a PhD fellowship funded by the Ministerio de Ciencia e Innovación (MCIN) FPI program (PRE2020-095611). Eduardo Oliver is a Ramón y Cajal fellow funded by the Spanish Ministry of Science and Innovation MCIN/AEI/ https://doi.org/10.13039/501100011033 and by “ESF Investing in your future” (RYC2020-028884-I and PID2021-123167OB-I00). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU), and the Pro CNIC Foundation and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/https://doi.org/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The relevance of the endothelium in cardiopulmonary disorders

  • Bastida-Casero, Laura de la
  • García-León, Bertha
  • Tura-Ceide, Olga
  • Oliver, Eduardo
22 p.-1 fig.-2 tab., The endothelium is a cell monolayer that lines vessels and separates tissues from blood flow. Endothelial cells (ECs) have a multitude of functions, including regulating blood flow and systemic perfusion through changes in vessel diameter. When an injury occurs, the endothelium is affected by altering its functions and structure, which leads to endothelial dysfunction, a characteristic of many vascular diseases. Understanding the role that the endothelium plays in pulmonary vascular and cardiopulmonary diseases, and exploring new therapeutic strategies is of utmost importance to advance clinically. Currently, there are several treatments able to improve patients’ quality of life, however, none are effective nor curative. This review examines the critical role of the endothelium in the pulmonary vasculature, investigating the alterations that occur in ECs and their consequences for blood vessels and potential molecular targets to regulate its alterations. Additionally, we delve into promising non-pharmacological therapeutic strategies, such as exercise and diet. The significance of the endothelium in cardiopulmonary disorders is increasingly being recognized, making ECs a relevant target for novel therapies aimed at preserving their functional and structural integrity., This research was supported by funding from Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (PID2021-123167OB-I00 and RED2022-134299-T), CSIC Talent Attraction program (20222AT010) and La Marató de TV3 Foundation (202336-30-31). L.d.l.B.-C. was a recipient of a predoctoral fellowship from Comunidad de Madrid (PIPF-2022/SAL-GL-24824). B.G.-L. was a recipient of a Severo Ochoa FPI predoctoral fellowship from Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (PRE2022-104403). O.T.-C. was supported by funding from Fondo de Investigación Sanitaria (FIS) Contratos Miguel Servet tipo II (CPII22/00006)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Reprogramming of GM-CSF-dependent alveolar macrophages through GSK3 activity modulation

  • Ríos, Israel
  • Herrero, Cristina
  • Torres-Torresano, Mónica
  • López-Navarro, Baltasar
  • Schiaffino, María Teresa
  • Díaz Crespo, Francisco
  • Nieto-Valle, Alicia
  • Samaniego, Rafael
  • Sierra-Palomares, Yolanda
  • Oliver, Eduardo
  • Revuelta-Salgado, Fernando
  • García-Luján, Ricardo
  • Sánchez-Mateos, Paloma
  • Delgado, Rafael
  • Puig-Kröger, Amaya
  • Corbí, Angel L.
Monocyte-derived macrophages recruited into inflamed tissues can acquire an array of functional states depending on the extracellular environment. Since the anti-inflammatory/pro-fibrotic macrophage profile is determined by MAFB, whose activity/protein levels are regulated by GSK3, we addressed the macrophage reprogramming potential of GSK3 modulation. GM-CSF-dependent (GM-MØ) and M-CSF-dependent monocyte-derived macrophages (M-MØ) exhibited distinct levels of inactive GSK3, and inhibiting GSK3 in GM-MØ led to the acquisition of transcriptional, phenotypic, and functional properties characteristic of M-MØ (enhanced expression of IL-10 and monocyte-recruiting factors, and higher efferocytosis). These reprogramming effects were also observed upon GSK3α/β knockdown and through GSK3 inhibition in ex vivo isolated human alveolar macrophages (AMØ). Notably, GSK3 downmodulation potentiated the transcriptional signature of interstitial macrophages (IMØ) while suppressing the AMØ-specific gene profile. Indeed, heightened levels of inactive GSK3 and MAFB-dependent proteins were observed in severe COVID-19 patients' lung macrophages, highlighting the GSK3-MAFB axis as a therapeutic target for macrophage reprogramming., This work was supported by grant PID2020- 114323RB- I00 from Ministerio de Ciencia e Innovación to ALC, Dirección General de Innovación e Investigación Tecnológica de la Comunidad de Madrid (RETARACOVID, P2022/BMD- 7274) to ALC, APK, PS- M, and RD, Instituto de Salud Carlos III (Grant PI23/00224 to APK, Grant PI21/00989 to RD), Red de Enfermedades Inflamatorias (RICORSRD21/0002/0034) from Instituto de Salud Carlos III and cofinanced by the Euopean Regional Devel-opment Fund 'A way to achieve Europe' (ERDF) and PRTR to APK, and PID2021- 123167OB- I00 from Ministerio de Ciencia, Innovación y Universidades and CSIC Talent Attraction program (20222AT010) to EO. This research work was also funded by the European Commission – NextGenerationEU (Regu-lation EU 2020/2094), through CSIC’s Global Health Platform (PTI Salud Global). AN- V was funded by YEI program contract from Comunidad de Madrid (PEJ- 2021- AI/BMD- 23327). IR was funded by a Formación de Personal Investigador predoctoral fellowship from Ministerio de Ciencia e Innovación (Grant PRE2021- 097080). Figures were created with Biorender.com., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Pharmacogenomics and chronotherapy of drug-induced cardioprotection in acute myocardial infarction

  • Clemente-Moragón, Agustín
  • Suárez-Barrientos, Aida
  • Gómez Tech, Mónica
  • López-Palomar Tech, Lucía Pilar
  • Callejas Alejano, Sergio
  • Martínez, Fernando
  • Fernández, José Francisco
  • Vega, María Cristina
  • Tech, Angela Pollán
  • Dopazo, Ana
  • Sánchez-Cabo, Fátima
  • Fuster, Valentín
  • Oliver, Eduardo
  • Ibáñez, Borja
Acute myocardial infarction remains a leading cause of morbidity and mortality worldwide. Pharmacogenetic and chronotherapeutic approaches are increasingly applied to optimize therapy in chronic cardiovascular diseases. While gene variants are known to influence long-term drug efficacy, their role in modulating drug-induced cardioprotection in acute conditions such as myocardial infarction is unclear. Similarly, the impact of circadian timing on cardioprotective responses remains insufficiently defined. To address these questions, we evaluated metoprolol as a model cardioprotective agent. Here we examine, in a non-pre-specified exploratory analysis of the METOCARD-CNIC trial (NCT01311700), the influence of ADRB1 Arg389Gly polymorphism and the time of AMI onset on metoprolol efficacy. We found that metoprolol reduced infarct size only in patients homozygous for the ADRB1 Arg389 allele, consistent with its genotype-dependent inhibition of neutrophil migration. In-silico docking and binding studies revealed unstable interactions of metoprolol with the Gly389 variant of ADRB1. Moreover, metoprolol was associated with reduced infarct size when AMI onset occurred between 6:00 and 12:00 h. Restricted cardioprotection to the light phase was confirmed in male mice and in neutrophil-specific Adrb1-knockout models. Collectively, these findings highlight the critical roles of genetic background and circadian timing in shaping the efficacy of acute cardioprotective therapies, supporting the rationale for personalized interventions in acute myocardial infarction., We particularly thank Andrés Hidalgo for sharing his knowledge of neutrophil behavior in IRI and providing us with some of the mouse lines used in this study (LysM-GFP and Mrp8-Cre), Francisco Javier Rosselló for sharing his expertise in statistics, Noemí Escalera for her assistance with volunteer recruitment and documents for the Ethics Committee, Bahia El Maimouni for her help as colony manager, and Carlos Galán for his expertise in graphic design. Adrb1FLOX/FLOX mice were provided by the UT Southwestern. We thank the CNIC Cellomics, Microscopy, Comparative Medicine, and Advanced Imaging Units. Simon Bartlett provided English editing. This study received funding from the Spanish Ministry of Science, Innovation and Universities (PID2022−140176OB-I00 to B.I.), the European Research Council (ERC) under the European Union Horizon 2020 Research and Innovation Programme (ERC-Consolidator Grant agreement No. 819775 to B.I.), and the Comunidad de Madrid through the Red Madrileña de Nanomedicina en Imagen Molecular (P2022/BMD-7403 RENIM-CM). E.O. is supported by funding from Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación MCIN/AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (PID2021-123167OB-I00), and CSIC Talent Attraction program (20222AT010). A.C-M. was supported by a fellowship from the Ministerio de Ciencia e Innovación (MCN) and ISCIII (FPU2017/01932). The CNIC is supported by the Instituto de Salud Carlos III (ISCIII), the Ministerio de Ciencia, Innovación y Universidades (MICIU) and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIU/AEI/10.13039/501100011033)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Vascular HIF2 Signaling Prevents Cardiomegaly, Alveolar Congestion, and Capillary Remodeling During Chronic Hypoxia

  • Albendea-Gómez, Teresa
  • Mendoza-Tamajón, S.
  • Castro-Mecinas, Rosana
  • Escobar, Beatriz
  • Ferreira Rocha, Susana
  • Urra-Balduz, Sonia
  • Nicolás-Ávila, José A.
  • Oliver, Eduardo
  • Villalba-Orero, María
  • Martín-Puig, Silvia
[Background] Hypoxia is associated with the onset of cardiovascular diseases including cardiac hypertrophy and pulmonary hypertension. HIF2 (hypoxia inducible factor 2) signaling in the endothelium mediates pulmonary arterial remodeling and subsequent elevation of the right ventricular systolic pressure during chronic hypoxia. Thus, novel therapeutic opportunities for pulmonary hypertension based on specific HIF2 inhibitors have been proposed. Nevertheless, HIF2 relevance beyond the pulmonary endothelium or in the cardiac adaptation to hypoxia remains elusive. Wt1 (Wilms tumor 1) lineage contributes to the heart and lung vascular compartments, including pericytes, endothelial cells, and smooth muscle cells., [Methods] Here, we describe the response to chronic hypoxia of a novel HIF2 mutant mouse model in the Wt1 lineage (Hif2/Wt1 cKO [conditional knockout]), characterizing structural and functional aspects of the heart and lungs by means of classical histology, immunohistochemistry, flow cytometry, echocardiography, and lung ultrasound analysis., [Results] Hif2/Wt1 cKO is protected against pulmonary remodeling and increased right ventricular systolic pressure induced by hypoxia, but displays alveolar congestion, inflammation, and hemorrhages associated with microvascular instability. Furthermore, lack of HIF2 in the Wt1 lineage leads to cardiomegaly, capillary remodeling, right and left ventricular hypertrophy, systolic dysfunction, and left ventricular dilation, suggesting pulmonary-independent cardiac direct roles of HIF2 in hypoxia. These structural defects are partially restored upon reoxygenation, while cardiac functional parameters remain altered., [Conclusions] Our results indicate that cardiopulmonary HIF2 signaling prevents excessive vascular proliferation during chronic hypoxia and define novel protective roles of HIF2 to warrant stable microvasculature and organ function., This project has been supported by grants to S. Martin-Puig (SMP) from Universidad Francisco de Vitoria (UFV), LeDucq Foundation: 17CVD04, the Spanish Ministry of Science and Innovation (Ministerio de Ciencia, Innovación y Universidades, MICIU): PID2020-117629RB-I00/AEI/10.13039/501100011033, Comunidad de Madrid (CM): S2022/BMD-7245 (CARDIOBOOST-CM), and Fundación Domingo Martínez: “Ayuda de Biomedicina 2023.” T. Albendea-Gomez was supported by a predoctoral award granted by CM/EU (European Union) and UFV: PEJD-2018-PRE/SAL-9529 and SMP project PID2020-117629RB-I00/AEI/10.13039/501100011033. S. Mendoza-Tamajon was funded by a predoctoral contract from the Spanish Ministry of Science and Innovation and European Regional Development Fund: PRE-2021-099445. R. Castro-Mecinas was funded by a contract from CM: PEJ-2021-AI/BMD-21926. B. Escobar was supported by SMP project 17CVD04. S. Urra-Balduz was funded by SMP project S2022/BMD-7245. J.A. Nicolas-Avila was supported by the University of California San Francisco (UCSF) Cardiovascular Research Institute department, the UCSF Dean’s office program, and the Young Investigator Competitive Award from the International Society for Heart Research. M. Villalba-Orero was funded by a Juan de la Cierva Incorporación Grant (IJCI-2016-27698). E. Oliver received funding from MICIU PID2021-123167OB-I00. E. Oliver and S. Martin-Puig were supported by the Spanish National Research Council (CSIC)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Vascular-Immune Cells Crosstalk and Microenvironment in Pulmonary Hypertension

  • Navarro-Llinares, Lola
  • García-León, Bertha
  • de la Bastida-Casero, Laura
  • Oliver, Eduardo
Pulmonary hypertension is a disease of the lung vasculature, which eventually leads to heart dysfunction. Despite the advances in the discovery and development of new treatments, most of them are aimed to palliate symptoms. Thus, it is crucial to identify novel potential targets directly acting on vascular remodeling. Further understanding of this pathological event is needed to completely describe the disease's mechanisms and effectively generate therapeutical strategies able to cure the disease. Here, we propose an integrative perspective of studying pulmonary hypertension based on the interactions between the vascular cells and their surroundings. This review describes the crosstalk between vascular cells and immune cells in the diseased vasculature, highlighting the central role of this axis and the importance of healthy cell-to-cell communication. Furthermore, we discuss the possibility of considering the pulmonary microenvironment as a key pathological factor in pulmonary hypertension, This work was supported by funding from Ministerio de Ciencia, Innovación y Universidades/Agencia Estatal de Investigación MCIN/ AEI/10.13039/501100011033 and by “ERDF A way of making Europe” (PID2021- 123167OB- I00, PID2024- 159407OB- I00 and RED2022- 134299- T), CSIC Talent Attraction program (20222AT010) and Ayudas especiales para la preparación de proyectos (2025AEP161), CIBERCV- CIBERNED collaborative funds (CV24PI04/2024), La Marató de TV3 Foundation (202336- 30- 31) and Ayudas para la investigación de la Fundación contra la Hipertensión Pulmonar. L.B.- C. was a recipient of a predoctoral fellowship from Comunidad de Madrid (PIPF- 2022/SAL- GL- 24824). B.G.- L. was a recipient of a Severo Ochoa FPI predoctoral fellowship from Ministerio de Ciencia e Innovación/Agencia Estatal de Investigación (PRE2022- 104403), Peer reviewed, Sin experimentacion animal ni uso de NAMs